International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines

Transplantation

Volumn 95, Issue 12, 2013, Pages 1455-1460

  Le Page, Amelia K ^a,b   Jager, Mischa M ^a,c   Kotton, Camille N ^d   Simoons Smit, Alberdina ^c   Rawlinson, William D ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cytomegalovirus; Guidelines; Prophylaxis; Survey; Transplantation

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; VALGANCICLOVIR;

CLINICAL DECISION MAKING; CONTROL STRATEGY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; GRAFT REJECTION; HEALTH CARE SURVEY; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MEDICAL PRACTICE; NEUTROPENIA; ORGAN TRANSPLANTATION; PATIENT CARE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; TREATMENT DURATION; VIRUS LOAD;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DEVELOPING COUNTRIES; EUROPE; GANCICLOVIR; GEOGRAPHY; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNATIONALITY; NEUTROPENIA; NORTH AMERICA; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; SOCIAL CLASS; SOCIETIES, MEDICAL;

EID: 84880132320     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31828ee12e     Document Type: Review

References (16)

1. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis 2009; 11: 195.
2. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
3. Breinig MK, Zitelli B, Starzl TE, et al. Epstein-Barr virus, cytomega-lovirus, and other viral infections in children after liver transplantation. J Infect Dis 1987; 156: 273.
4. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
5. Zuk DM, Humar A, Weinkauf JG, et al. An international survey of cytomegalovirus management practices in lung transplantation. Tr a n s-plantation 2010; 90: 672.
6. Hodson EM, Craig JC, Strippoli GF, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; CD003774.
7. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplantation 2004; 4: 1219.
8. Burroughs M, Sobanjo A, Florman S, et al. Cytomegalovirus matching does not predict symptomatic disease in intestinal transplantation. Transplant Proc 2002; 34: 946.
9. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 928.
10. Kalil AC, Levitsky J, Lyden E, et al. The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
11. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
12. Bhat V, McIntyre M, Meyers T. Efficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients. P T 2010; 35: 676.
13. Luan FL, Kommareddi M, Ojo AO. Impact of cytomegalovirus disease in D+/R-kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 2011; 11: 1936.
14. National Institute for Biological Standards and Control. 1st WHO International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques. Hertfordshire: United Kingdom; 2010.
15. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032.
16. Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res 2001; 35: 1347.